27338800|t|NLRC5 promotes cell proliferation via regulating the AKT / VEGF-A signaling pathway in hepatocellular carcinoma
27338800|a|NLRC5, a newly found member of the NLR family and the largest member of nucleotide-binding, has been reported to regulate immune responses and is associated with hepatocellular carcinoma (HCC). We investigated the mechanisms and signaling pathways of NLRC5 in HCC progression. Increased expression of NLRC5, vascular endothelial growth factor-A (VEGF-A) were found in human HCC tissue. There was a positive correlation between NLRC5 and VEGF-A expression and cell proliferation were enhanced in NLRC5 - overexpressing HepG2 cells, but inhibited in cells with NLRC5 silencing treatment. Interestingly, we found that up-regulation of NLRC5 also coordinated the activation of PI3K/AKT signaling pathway. An AKT inhibitor LY294002 blocked VEGF-A expression and AKT phosphorylation in HepG2 cells and NLRC5 - overexpressing HepG2 cells. These results demonstrate that NLRC5 promotes HCC progression via the AKT / VEGF-A signaling pathway.
27338800	0	5	NLRC5	T116,T123	C2932687
27338800	6	14	promotes	T052	C0033414
27338800	15	33	cell proliferation	T043	C0596290
27338800	53	56	AKT	T044	C1515844
27338800	59	83	VEGF-A signaling pathway	T044	C3271788
27338800	87	111	hepatocellular carcinoma	T191	C2239176
27338800	112	117	NLRC5	T116,T123	C2932687
27338800	121	126	newly	T078	C0750546
27338800	133	139	member	T096	C1551024
27338800	147	157	NLR family	T116,T123	C4277661
27338800	166	173	largest	T081	C0443228
27338800	174	180	member	T096	C1551024
27338800	184	202	nucleotide-binding	T044	C1148916
27338800	213	221	reported	T170	C0684224
27338800	225	233	regulate	T080	C0243148
27338800	234	250	immune responses	T042	C0301872
27338800	258	273	associated with	T080	C0332281
27338800	274	298	hepatocellular carcinoma	T191	C2239176
27338800	300	303	HCC	T191	C2239176
27338800	309	321	investigated	T169	C1292732
27338800	326	336	mechanisms	T169	C0441712
27338800	341	359	signaling pathways	T044	C0037080
27338800	363	368	NLRC5	T116,T123	C2932687
27338800	372	375	HCC	T191	C2239176
27338800	376	387	progression	T191	C0178874
27338800	389	398	Increased	T081	C0205217
27338800	399	409	expression	T045	C1171362
27338800	413	418	NLRC5	T116,T123	C2932687
27338800	420	456	vascular endothelial growth factor-A	T116,T123	C0078058
27338800	458	464	VEGF-A	T116,T123	C0078058
27338800	480	485	human	T016	C0086418
27338800	486	489	HCC	T191	C2239176
27338800	490	496	tissue	T024	C0040300
27338800	510	518	positive	T033	C1446409
27338800	519	530	correlation	T080	C1707520
27338800	539	544	NLRC5	T116,T123	C2932687
27338800	549	555	VEGF-A	T116,T123	C0078058
27338800	556	566	expression	T045	C1171362
27338800	571	589	cell proliferation	T043	C0596290
27338800	595	603	enhanced	T052	C2349975
27338800	607	612	NLRC5	T116,T123	C2932687
27338800	615	629	overexpressing	T045	C1514559
27338800	630	641	HepG2 cells	T025	C2717940
27338800	647	656	inhibited	T080	C0311403
27338800	660	665	cells	T025	C0007634
27338800	671	676	NLRC5	T116,T123	C2932687
27338800	677	686	silencing	T045	C0598496
27338800	727	740	up-regulation	T044	C0041904
27338800	744	749	NLRC5	T116,T123	C2932687
27338800	755	766	coordinated	T169	C0700114
27338800	771	781	activation	T052	C1879547
27338800	785	811	PI3K/AKT signaling pathway	T169	C2984369
27338800	816	838	AKT inhibitor LY294002	T109,T121	C0251991
27338800	839	846	blocked	T169	C0332206
27338800	847	853	VEGF-A	T116,T123	C0078058
27338800	854	864	expression	T045	C1171362
27338800	869	872	AKT	T116,T126	C0164786
27338800	873	888	phosphorylation	T044	C1158886
27338800	892	903	HepG2 cells	T025	C2717940
27338800	908	913	NLRC5	T116,T123	C2932687
27338800	916	930	overexpressing	T045	C1514559
27338800	931	942	HepG2 cells	T025	C2717940
27338800	950	957	results	T033	C0683954
27338800	975	980	NLRC5	T116,T123	C2932687
27338800	981	989	promotes	T052	C0033414
27338800	990	993	HCC	T191	C2239176
27338800	994	1005	progression	T191	C0178874
27338800	1014	1017	AKT	T044	C1515844
27338800	1020	1044	VEGF-A signaling pathway	T044	C3271788